Eli Lilly and Sanofi-Aventis have agreed to cap insulin prices at $35 per monthly prescription for uninsured New Yorkers for five years, according to a statement from the office of New York Attorney General Letitia James.
- Implementing streamlined pharmacy process to automatically inform cash-paying consumers about the capped pricing
- Also committing to offering free insulin products to high-need populations
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2023 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.